Has Mobocertinib been included in domestic medical insurance and coverage?

Mobocertinib has been officially launched in China, providing a new targeted treatment option for some patients with non-small cell lung cancer (NSCLC). However, the drug has not yet been included in the domestic medical insurance system, so patients need to pay out-of-pocket when purchasing it domestically, which is relatively expensive. Due to limited drug supply channels in China, direct purchase may be difficult. It is recommended that patients consult the local hospital pharmacy for detailed information on the specific drug purchase procedures when seeking medical treatment.

Although moboxetinib is already on the market in China, its price is still a big burden for some patients because it has not yet been included in medical insurance. Original medicines are more expensive, with each box usually costing around 7,000 to 8,000 yuan. At the same time, because the market has just opened, hospital stocks may be limited. Therefore, patients need to confirm the source of the medicine in advance when choosing to purchase it, and arrange a reasonable medication plan under the guidance of a doctor to ensure the continuity and safety of treatment.

In overseas markets, mobosetinib has both original drugs and generic drugs available. The original drugs mainly include the Hong Kong version and the Japanese Takeda version. The price is usually around 7,000 to 8,000 yuan, and the cost is relatively high. In comparison, the price of generic drugs is more affordable. For example, the Laotian version of Moboxetinib is about 3,000 yuan per box, which is almost half of the original drug. The ingredients of the drug are basically the same as the original drug, providing patients with an economically feasible alternative.

For patients who need to use moboxetinib, they should choose a suitable drug purchase channel under the guidance of a doctor. Domestic patients can give priority to purchasing it through regular hospital pharmacies and pay attention to medical insurance trends. If the drug is included in medical insurance in the future, treatment costs will be significantly reduced. Overseas channels are suitable for patients who need a more economical solution, but they need to ensure that the source of the medicine is regular, safe and reliable. Generally speaking, reasonable planning of drug purchase channels and budget is crucial to ensuring patient efficacy and drug safety.

Reference link:https://www.drugs.com